"RGX-202 is the only next generation gene therapy for Duchenne in a pivotal phase trial. The new data from the age 1-3 cohort builds on the favorable safety and efficacy profile seen in ages 4 and ...

I’ve spent the past week typing on an early unit of the Norbauer Seneca, a mechanical keyboard that’s entirely custom, from its Topre-like electrocapacitive switches to its astonishingly ...

Languages: English In 2021, the federal government offered a $3,600 expanded child tax credit, but many parents may have been unaware of the credit and missed out on the payment if they didn't file.

RGX-202 shows the highest reported microdystrophin levels in ambulatory patients age 8+ among gene therapies. Regenxbio plans to submit a BLA for RGX-202 in mid-2026, with Phase 3 enrollment ...

A 3,600-year-old tomb has been discovered 23 feet below ground in Abydos, Egypt. The burial site includes a limestone chamber surrounded by mudbrick vaults, but the king's identity remains a ...

Archaeologists have unearthed the tomb of a yet unknown Egyptian pharaoh who ruled 3,600 years ago during a time of political instability in the region. The royal tomb was found at a depth of ...

Huawei introduced the world's first tri-fold phone, the Mate XT Ultimate, in its home country late last year. A global release seemed unlikely, but after breaking preorder records -- even before ...

RGX-202, a one-time gene therapy designed to treat Duchenne muscular dystrophy (DMD), has been well tolerated in an ongoing clinical trial, with no serious side effects reported. Interim data from the ...

US gene therapy company Regenxbio (Nasdaq: RGNX) has reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, an ...

If you’ve been shopping at ALDI to try to cut costs, it’s an increasingly common strategy. A recent food price outlook released by the U.S. Department of Agriculture (USDA) predicts price increases in ...

ROCKVILLE, MD, USA I March 19, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE ® trial of ...